Browsing category:

OTC and Compounding Product


With a 5.6 billion dollar market worldwide for treating glaucoma, research and development of new treatments are both needed and inevitable. Travoprost, currently a safe and efficacious therapy, continues to be a reliable treatment for the onslaught of patients around the globe suffering from glaucoma. With no cure for this debilitating eye disease, glaucoma is[…]

Read More

Patients with non-small cell lung cancer, also known as NSCLC, are anxiously awaiting a decision from the FDA’s Oncologic Drugs Advisory Committee regarding Eli Lilly’s introduction of Necitumumab to the already formidable Gemcitabine and Cisplatin combination. Both Gemcitabine and Cisplatin are currently the first line-treatment for patients diagnosed with NSCLC, and the addition of Necitumumab[…]

Read More

Known as the brand name Byetta in the United States, which is marketed by AstraZeneca, Exenatide is a GLP-1 analog that is currently offered as an injectable treatment for type 2 diabetes. In mid-January 2015 Oramed Pharmaceuticals was granted a patent in Israel for the oral administration of Exenatide. As an effectual therapy for patients[…]

Read More

Known as the brand name anti-epileptic drug Dilantin, Phenytoin has recently piqued the interests of Multiple Sclerosis research and development teams. Study results shared from the National Hospital for Neurology and Neurosurgery in London have been hopeful for patients with MS who were treated with Phenytoin, in response to their cases of acute optic neuritis.[…]

Read More

Bimatoprost opthamolic solution has been known for being effectual at lowering intraocular pressure in adult patients. A new benefit of Bimatoprost has stolen the pharmaceutical headlines, however, with the advent of Latisse, for treating hypotrichosis of the eyelashes. Touted by long time movie star and model Brooke Shields, Latisse is recommended for people who wish[…]

Read More

In late 2014 the FDA approved Dorzolamide Hydrochloride, to be used in conjunction with Timolol Maleate for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Known as the brand name eye drop Cosopt Opthamolic Solution, which is marketed by Lannett Company Inc., this solution has proven to be both[…]

Read More

The culmination of a six year study led by cardiologists at Duke University showcased the phenomenal benefits of cholesterol lowering agents Ezetimibe and Simvastatin, also known as the brand name drug Vytorin. Study results were conclusive in determining the importance of low LDL levels of cholesterol, with ultra-low levels being ideal. Not only does lowering[…]

Read More

On January 15, 2015 Pernix Therapeutics excitedly announced an FDA acceptance for a priority review of Sumatriptan and Naproxen Sodium, also known as Treximet, for adolescent patients. Pernix expects an FDA approval by the second quarter of 2015, which would greatly benefit the adolescent patient population suffering from migraines. This anticipated approval would be specific[…]

Read More

The close of 2014 brought exciting news for patients suffering from dementia with the announcement that Tadalafil, a commonly used drug that treats erectile dysfunction, is being tested as a treatment for dementia. The Alzheimer’s Drug Discovery Foundation and the Alzheimer’s Society UK shared the news of their partnership and funding, which would be earmarked[…]

Read More

As the most commonly prescribed treatment for glaucoma, Latanoprost has taken the pharmaceutical headlines by storm with the latest study data revelations. At the end of December 2014 The Lancet published remarkable study results indicating that the use of Latanoprost reduced the risk of glaucoma by over 50 percent when taken for two years’ time.[…]

Read More